The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...
Moderna CEO Stéphane Bancel deflected concerns about the new presidential administration's potential impact on life sciences ...
Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...
Earnings season continues, and we're here to spotlight the companies expected to report their financial results on the next ...
Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $2.68 per share, versus earnings of 55 cents per share in the year-ago period. Moderna projects quarterly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results